Oral contraceptive use and psychiatric disorders in a nationally representative sample of women

Archives of Women's Mental Health

Volumn 18, Issue 1, 2015, Pages 103-111

  Cheslack Postava, Keely ^a   Keyes, Katherine M ^a   Lowe, Sarah R ^a   Koenen, Karestan C ^a  

^a Department of Medicine   (United States)

Author keywords

Generalized anxiety disorder; Hormonal contraceptives; Major depressive disorder; Oral contraceptives; Panic disorder

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ANXIETY DISORDERS; CHEMICALLY INDUCED; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ETHNIC GROUP; FEMALE; HEALTH SURVEY; HUMAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PANIC DISORDER; PREVALENCE; PSYCHOLOGY; SOCIOECONOMICS; UNITED STATES;

ADOLESCENT; ADULT; ANXIETY DISORDERS; CONTRACEPTIVES, ORAL; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ETHNIC GROUPS; FEMALE; HEALTH SURVEYS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PANIC DISORDER; PREVALENCE; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84934757978     PISSN: 14341816     EISSN: 14351102     Source Type: Journal    
DOI: 10.1007/s00737-014-0453-4     Document Type: Article

References (43)

1. Abraham S, Luscombe G, Soo I (2003) Oral contraception and cyclic changes in premenstrual and menstrual experiences. J Psychosom Obstet Gynaecol 24(3):185–193
2. Altshuler LL, Hendrick V, Cohen LS (1998) Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry 59(Suppl 2):29–33
3. Arpels JC (1996) The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. J Reprod Med 41(9):633–639
4. Brambilla F, Biggio G, Pisu MG, Bellodi L, Perna G, Bogdanovich-Djukic V, Purdy RH, Serra M (2003) Neurosteroid secretion in panic disorder. Psychiatry Res 118(2):107–116
5. Burkman RT, Collins JA, Shulman LP, Williams JK (2001) Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185(2 Supplement):S4–S12
6. Duke JM, Sibbritt DW, Young AF (2007) Is there an association between the use of oral contraception and depressive symptoms in young Australian women? Contraception 75(1):27–31
7. Fleischman DS, Navarrete CD, Fessler DM (2010) Oral contraceptives suppress ovarian hormone production. Psychol Sci 21(5):750–752
8. Greco T, Graham CA, Bancroft J, Tanner A, Doll HA (2007) The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 76(1):8–17
9. Halbreich U, Kahn LS (2001) Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 15(10):797–817
10. Jensen JT, Speroff L (2000) Health benefits of oral contraceptives. Obstet Gynecol Clin N Am 27(4):705–721
11. Joffe H, Cohen LS (1998) Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry 44(9):798–811
12. Joffe H, Cohen LS, Harlow BL (2003) Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 189(6):1523–1530
13. Kaspi SP, Otto MW, Pollack MH, Eppinger S, Rosenbaum JF (1994) Premenstrual exacerbation of symptoms in women with panic disorder. J Anxiety Disord 8(2):131–138
14. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21(3):169–184
15. Keyes KM, Cheslack-Postava K, Westhoff C, Heim CM, Haloossim MR, Walsh K, Koenen KC (2013) Hormonal contraception use is associated with reduced depressive symptoms: a national study of sexually active women in the US. Am J Epidemiol 178(9):1378–1388
16. Klein DF (1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 50(4):306–317
17. Logue CM, Moos RH (1986) Perimenstrual symptoms: prevalence and risk factors. Psychosom Med 48(6):388–414
18. Lopez LM, Kaptein AA, Helmerhorst FM (2012) Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2, CD006586. doi:10.1002/14651858.CD006586.pub4
19. Moreau C, Cleland K, Trussell J (2007) Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 76(4):267–272
20. Mosher WD, Jones J (2010) Use of contraception in the United States: 1982–2008. Center for Disease Control and Prevention, Washington, DC
21. Natale V, Albertazzi P (2006) Mood swings across the menstrual cycle: a comparison between oral contraceptive users and non-users. Biol Rhythm Res 37(6):489–495
22. National Center for Health Statistics (a). National Health and Nutrition Examination Survey, 2013–2014 overview. http://www.cdc.gov/nchs/data/nhanes/nhanes_13_14/2013-14_overview_brochure.pdf. Accessed 04/05/13
23. National Center for Health Statistics (b). NHANES response rates and population totals. http://www.cdc.gov/nchs/nhanes/response_rates_cps.htm. Accessed November 6, 2013
24. National Comorbidity Study. Table 2. 12-month prevalence of DSM-IV/WMH-CIDI disorders by sex and cohort (n = 9282). http://www.hcp.med.harvard.edu/ncs/ftpdir/NCS-R_12-month_Prevalence_Estimates.pdf. Accessed 05/01/2013
25. Nillni YI, Toufexis DJ, Rohan KJ (2011) Anxiety sensitivity, the menstrual cycle, and panic disorder: a putative neuroendocrine and psychological interaction. Clin Psychol Rev 31(7):1183–1191
26. Oinonen KA, Mazmanian D (2002) To what extent do oral contraceptives influence mood and affect? J Affect Disord 70(3):229–240
27. Payne JL (2003) The role of estrogen in mood disorders in women. Int Rev Psychiatry 15(3):280–290
28. Payne JL, Roy PS, Murphy-Eberenz K, Weismann MM, Swartz KL, McInnis MG, Nwulia E, Mondimore FM, MacKinnon DF, Miller EB, Nurnberger JI, Levinson DF, DePaulo JR Jr, Potash JB (2007) Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 99(1–3):221–229
29. Peters L, Clark D, Carroll F (1998) Are computerized interviews equivalent to human interviewers? CIDI-Auto versus CIDI in anxiety and depressive disorders. Psychol Med 28(4):893–901
30. Rucci P, Gherardi S, Tansella M, Piccinelli M, Berardi D, Bisoffi G, Corsino MA, Pini S (2003) Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord 76(1–3):171–181
31. Schultz-Zehden B, Boschitsch E (2006) User experience with an oral contraceptive containing ethinylestradiol 30mug and drospirenone 3 mg (Yasmin ®) in clinical practice. Treat Endocrinol 5(4):251–256
32. Short M (2009) User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 microg (Yasminelle) in clinical practice: a multi-country, questionnaire-based study. Clin Drug Investig 29(3):153–159
33. Stuart JE, Secura GM, Zhao Q, Pittman ME, Peipert JF (2013) Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users. Obstet Gynecol 121(2 Pt 1):330–336
34. Taneepanichskul S, Patrachai S (1998) Effects of long-term treatment with depot medroxy progesterone acetate for contraception on estrogenic activity. J Med Assoc Thai 81(12):944–946
35. Targum SD, Caputo KP, Ball SK (1991) Menstrual cycle phase and psychiatric admissions. J Affect Disord 22(1–2):49–53
36. Toffol E, Heihinheimo O, Koponen P, Luoto R, Partonen T (2011) Hormonal contraception and mental health: results of a population-based study. Hum Reprod 26(11):3085–3093
37. Walker A, Bancroft J (1990) Relationship between premenstrual symptoms and oral contraceptive use: a controlled study. Psychosom Med 52(1):86–96
38. Westhoff CL, Heartwell S, Edwards S, Zieman M, Stuart G, Cwiak C, Davis A, Robilotto T, Cushman L, Kalmuss D (2007) Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 196(4):412, e411-416
39. WHO (1997) CIDI-Auto version 2.1: Administrator’s guide and reference. Training and Reference Centre for WHO CIDI, Sydney
40. Wittchen HU (1994) Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 28(1):57–84
41. Young EA, Altemus M (2004) Puberty, ovarian steroids, and stress. Ann N Y Acad Sci 1021(1):124–133
42. Young EA, Midgley AR, Carlson NE, Brown MB (2000) Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. Arch Gen Psychiatry 57(12):1157–1162
43. Zeidan MA, Igoe SA, Linnman C, Vitalo A, Levine JB, Klibanski A, Goldstein JM, Milad MR (2011) Estradiol modulates medial prefrontal cortex and amygdala activity during fear extinction in women and female rats. Biol Psychiatry 70(10):920–927